|
|
|||||||
Malignant Lymphomas |
From the Department of Internal Medicine V, University of Heidelberg (PD, MR, MH, ADH); Department of Internal Medicine, Westpfalz-Klinikum, Kaiserslautern (BS); Department of Medicine II, University of Schleswig-Holstein, Kiel (MK, CP); Department of Hematology, Asklepios Klinik St. Georg, Hamburg, Germany (BS, NS)
Correspondence: Peter Dreger, Department of Medicine V, University of Heidelberg, INF 410, 69120 Heidelberg, Germany. E-mail: peter.dreger{at}med.uni-heidelberg.de
Background and Objectives: Autologous stem cell transplantation (ASCT) is effective in mantle cell lymphoma (MCL). We investigated whether incorporation of rituximab into the high-dose regimen might further improve the results of ASCT in patients with MCL.
Design and Methods: In a prospective phase II study, patients with newly diagnosed MCL were treated with a sequential dose-escalating therapy comprising standard chemotherapy for remission induction, intensive ara-C-containing chemotherapy for mobilization of stem cells, and myeloablative therapy followed by ASCT. The myeloablative regimen consisted of total body irradiation and high-dose cyclophosphamide supplemented with two doses (375 mg/m3) of rituximab. Outcome parameters (toxicity, clinical and molecular response as assessed by allele-specific IGH real-time quantitative polymerase chain reaction (RQ-PCR), event-free survival, and overall survival) were compared with those of 34 historical controls treated identically but without rituximab.
Results: Thirty-four patients were accrued. Whereas engraftment, toxicity and clinical response were not different from those in controls, event-free survival was significantly increased with rituximab (not reached vs. 43 months; hazard ratio 0.38; p=0.036). This was associated with a trend for a superior molecular response rate in 11 study vs. 10 control patients with a marker available (73% vs. 30%, p=0.086) despite similar levels of lymphoma contamination of the stem cell inocula infused.
Interpretation and Conclusions: Incorporation of two standard doses of rituximab into the myeloablative regimen might improve outcome of upfront ASCT for MCL, allowing long-term disease control to an extent previously not reached in this disease.
Key words: MCL, autologous stem cell transplantation, rituximab.
This article has been cited by other articles:
![]() |
C. H. Geisler, A. Kolstad, A. Laurell, N. S. Andersen, L. B. Pedersen, M. Jerkeman, M. Eriksson, M. Nordstrom, E. Kimby, A. M. Boesen, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood, October 1, 2008; 112(7): 2687 - 2693. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |